Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

Inclusion Criteria:

• primary, end-stage hip osteoarthritis requiring total hip arthroplasty

Exclusion Criteria:

• inflammatory arthropathies
• liver disorders
• neoplastic conditions
• clotting disorders